Drug Database · Clinicians

Pemetrexed

Brands (47) Cartrexed, Pemirex, Alimta…Show all

Antineoplastic (folic acid analogue); Antineoplastic agent (folic acid analogue); and others PH FDA category

Rx · Prescription drug60 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID f5a860f3-37ec-429c-ae04-9c88d7c55c08, version date May 19, 2023 (Alimta · Eli Lilly and Company). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
  • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.
  • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE ALIMTA ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. (1.1) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.

(1.1) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (1.1) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.

(1.1) Limitations of Use: ALIMTA is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. (1.1) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. (1.2) 1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) ALIMTA ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.

Limitations of Use: ALIMTA is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer [see Clinical Studies (14.1)]. 1.2 Mesothelioma ALIMTA is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

Contraindications

4 CONTRAINDICATIONS ALIMTA is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed [see Adverse Reactions (6.1)]. History of severe hypersensitivity reaction to pemetrexed. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • The recommended dose of ALIMTA administered with pembrolizumab and platinum chemotherapy in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes, administered after pembrolizumab and prior to platinum chemotherapy, on Day 1 of each 21-day cycle. (2.1)
  • The recommended dose of ALIMTA, administered as a single agent or with cisplatin, in patients with creatinine clearance of 45 mL/minute or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. (2.1, 2.2)
  • Initiate folic acid 400 mcg to 1000 mcg orally, once daily, beginning 7 days prior to the first dose of ALIMTA and continue until 21 days after the last dose of ALIMTA. (2.4)
  • Administer vitamin B12, 1 mg intramuscularly, 1 week prior to the first dose of ALIMTA and every 3 cycles. (2.4)
  • Administer dexamethasone 4 mg orally, twice daily the day before, the day of, and the day after ALIMTA administration. (2.4)
2.1 Recommended Dosage for Non-Squamous

2.1 Recommended Dosage for Non-Squamous NSCLC The recommended dose of ALIMTA when administered with pembrolizumab and platinum chemotherapy for the initial treatment of metastatic non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes administered after pembrolizumab and prior to carboplatin or cisplatin on Day 1 of each 21-day cycle for 4 cycles. Following completion of platinum-based therapy, treatment with ALIMTA with or without pembrolizumab is administered until disease progression or unacceptable toxicity.

Please refer to the full prescribing information for pembrolizumab and for carboplatin or cisplatin. The recommended dose of ALIMTA when administered with cisplatin for initial treatment of locally advanced or metastatic non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes administered prior to cisplatin on Day 1 of each 21-day cycle for up to six cycles in the absence of disease progression or unacceptable toxicity.

The recommended dose of ALIMTA for maintenance treatment of non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity after four cycles of platinum-based first-line chemotherapy. The recommended dose of ALIMTA for treatment of recurrent non-squamous NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.

2.2 Recommended Dosage for Mesothelioma

2.2 Recommended Dosage for Mesothelioma The recommended dose of ALIMTA when administered with cisplatin in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.

2.3 Renal Impairment

2.3 Renal Impairment ALIMTA dosing recommendations are provided for patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater [see Dosage and Administration (2.1, 2.2)]. There is no recommended dose for patients whose creatinine clearance is less than 45 mL/min [see Use in Specific Populations (8.6)].

2.4 Premedication and Concomitant Medications to Mitigate Toxicity Vitamin Supplementation

2.4 Premedication and Concomitant Medications to Mitigate Toxicity Vitamin Supplementation Initiate folic acid 400 mcg to 1000 mcg orally once daily, beginning 7 days before the first dose of ALIMTA and continuing until 21 days after the last dose of ALIMTA [see Warnings and Precautions (5.1)]. Administer vitamin B12, 1 mg intramuscularly, 1 week prior to the first dose of ALIMTA and every 3 cycles thereafter.

Subsequent vitamin B12 injections may be given the same day as treatment with ALIMTA [see Warnings and Precautions (5.1)]. Do not substitute oral vitamin B12 for intramuscular vitamin B12. Corticosteroids Administer dexamethasone 4 mg orally twice daily for three consecutive days, beginning the day before each ALIMTA administration.

2.5 Dosage Modification of Ibuprofen in Patients with Mild to Moderate Renal Impairment…

2.5 Dosage Modification of Ibuprofen in Patients with Mild to Moderate Renal Impairment Receiving ALIMTA In patients with creatinine clearances between 45 mL/min and 79 mL/min, modify administration of ibuprofen as follows [see Warnings and Precautions (5.6), Drug Interactions (7) and Clinical Pharmacology (12.3)]: Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of ALIMTA. Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant administration of ibuprofen cannot be avoided.

2.6 Dosage Modifications for Adverse Reactions

2.6 Dosage Modifications for Adverse Reactions Obtain complete blood count on Days 1, 8, and 15 of each cycle. Assess creatinine clearance prior to each cycle. Do not administer ALIMTA if the creatinine clearance is less than 45 mL/min. Delay initiation of the next cycle of ALIMTA until: recovery of non-hematologic toxicity to Grade 0-2, absolute neutrophil count (ANC) is 1500 cells/mm 3 or higher, and platelet count is 100,000 cells/mm 3 or higher.

Upon recovery, modify the dosage of ALIMTA in the next cycle as specified in Table 1. For dosing modifications for cisplatin, carboplatin, or pembrolizumab, refer to their prescribing information. Table 1: Recommended Dosage Modifications for Adverse Reactions a a National Cancer Institute Common Toxicity Criteria for Adverse Events version 2 (NCI CTCAE v2).

Toxicity in Most Recent Treatment Cycle ALIMTA Dose Modification for Next Cycle Myelosuppressive toxicity [see Warnings and Precautions (5.1)] ANC less than 500/mm 3 and platelets greater than or equal to 50,000/mm 3 OR Platelet count less than 50,000/mm 3 without bleeding. 75% of previous dose Platelet count less than 50,000/mm 3 with bleeding 50% of previous dose Recurrent Grade 3 or 4 myelosuppression after 2 dose reductions Discontinue Non-hematologic toxicity Any Grade 3 or 4 toxicities EXCEPT mucositis or neurologic toxicity OR Diarrhea requiring hospitalization 75% of previous dose Grade 3 or 4 mucositis 50% of previous dose Renal toxicity [see Warnings and Precautions (5.2)] Withhold until creatinine clearance is 45 mL/min or greater Grade 3 or 4 neurologic toxicity Permanently discontinue Recurrent Grade 3 or 4 non-hematologic toxicity after 2 dose reductions Permanently discontinue Severe and life-threatening Skin Toxicity [see Warnings and Precautions (5.3)] Permanently discontinue Interstitial Pneumonitis [see Warnings and Precautions (5.4)] Permanently discontinue

2.7 Preparation for Administration

2.7 Preparation for Administration ALIMTA is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Calculate the dose of ALIMTA and determine the number of vials needed. Reconstitute ALIMTA to achieve a concentration of 25 mg/mL as follows: Reconstitute each 100-mg vial with 4.2 mL of 0.9% Sodium Chloride Injection, USP (preservative-free) Reconstitute each 500-mg vial with 20 mL of 0.9% Sodium Chloride Injection, USP (preservative-free) Do not use calcium-containing solutions for reconstitution.

Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in color from colorless to yellow or green-yellow. FURTHER DILUTION IS REQUIRED prior to administration. Store reconstituted, preservative-free product under refrigerated conditions [2-8°C (36-46°F)] for no longer than 24 hours from the time of reconstitution.

Discard vial after 24 hours. Inspect reconstituted product visually for particulate matter and discoloration prior to further dilution. If particulate matter is observed, discard vial. Withdraw the calculated dose of ALIMTA from the vial(s) and discard vial with any unused portion. Further dilute ALIMTA with 0.9% Sodium Chloride Injection (preservative-free) to achieve a total volume of 100 mL for intravenous infusion.

Store diluted, reconstituted product under refrigerated conditions [2-8°C (36-46°F)] for no more than 24 hours from the time of reconstitution. Discard after 24 hours.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations, pharmacokinetics)

2.3 Renal Impairment ALIMTA dosing recommendations are provided for patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater [see Dosage and Administration (2.1, 2.2)]. There is no recommended dose for patients whose creatinine clearance is less than 45 mL/min [see Use in Specific Populations (8.6)].

2.5 Dosage Modification of Ibuprofen in Patients with Mild to Moderate Renal Impairment Receiving ALIMTA In patients with creatinine clearances between 45 mL/min and 79 mL/min, modify administration of ibuprofen as follows [see Warnings and Precautions (5.6), Drug Interactions (7) and Clinical Pharmacology (12.3)]: Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of ALIMTA. Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant administration of ibuprofen cannot be avoided.

8.6 Patients with Renal Impairment ALIMTA is primarily excreted by the kidneys. Decreased renal function results in reduced clearance and greater exposure (AUC) to ALIMTA compared with patients with normal renal function [Warnings and Precautions (5.2, 5.6) and Clinical Pharmacology (12.3)]. No dose is recommended for patients with creatinine clearance less than 45 mL/min [see Dosage and Administration (2.3)].

Patients with Renal Impairment Pharmacokinetic analyses of pemetrexed included 127 patients with impaired renal function. Plasma clearance of pemetrexed decreases as renal function decreases, with a resultant increase in systemic exposure.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of ALIMTA in pediatric patients have not been established. The safety and pharmacokinetics of ALIMTA were evaluated in two clinical studies conducted in pediatric patients with recurrent solid tumors (NCT00070473 N=32 and NCT00520936 N=72). Patients in both studies received concomitant vitamin B12 and folic acid supplementation and dexamethasone.

No tumor responses were observed. Adverse reactions observed in pediatric patients were similar to those observed in adults. Single-dose pharmacokinetics of ALIMTA were evaluated in 22 patients age 4 to 18 years enrolled in NCT00070473 were within range of values in adults.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 3,946 patients enrolled in clinical studies of ALIMTA, 34% were 65 and over and 4% were 75 and over. No overall differences in effectiveness were observed between these patients and younger patients. The incidences of Grade 3-4 anemia, fatigue, thrombocytopenia, hypertension, and neutropenia were higher in patients 65 years of age and older as compared to younger patients: in at least one of five randomized clinical trials. [see Adverse Reactions (6.1) and Clinical Studies (14.1, 14.2)].

Administration

2.7 Preparation for Administration ALIMTA is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Calculate the dose of ALIMTA and determine the number of vials needed. Reconstitute ALIMTA to achieve a concentration of 25 mg/mL as follows: Reconstitute each 100-mg vial with 4.2 mL of 0.9% Sodium Chloride Injection, USP (preservative-free) Reconstitute each 500-mg vial with 20 mL of 0.9% Sodium Chloride Injection, USP (preservative-free) Do not use calcium-containing solutions for reconstitution. Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in color from colorless to yellow or green-yellow. FURTHER DILUTION IS REQUIRED prior to administration. Store reconstituted, preservative-free product under refrigerated conditions [2-8°C (36-46°F)] for no longer than 24 hours from the time of reconstitution. Discard vial after 24 hours. Inspect reconstituted product visually for particulate matter and discoloration prior to further dilution. If particulate matter is observed, discard vial. Withdraw the calculated dose of ALIMTA from the vial(s) and discard vial with any unused portion. Further dilute ALIMTA with 0.9% Sodium Chloride Injection (preservative-free) to achieve a total volume of 100 mL for intravenous infusion. Store diluted, reconstituted product under refrigerated conditions [2-8°C (36-46°F)] for no more than 24 hours from the time of reconstitution. Discard after 24 hours.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for injection: 100 mg, 500 mg
  • Lyophilized powder for iv infusion: 1 g, 100 mg, 300 mg, 500 mg
  • Lyophilized powder for intravenous infusion: 100 mg, 500 mg
  • Lyophilized powder for concentrate for solution for infusion: 100 mg, 500 mg
  • Lyophilized powder for injection for i.v. infusion: 100 mg, 500 mg
  • Powder for concentrate for solution for infusion: 100 mg, 500 mg
  • Lyophilized powder for i.v. infusion: 100 mg, 500 mg
  • ) solution for injection: 10 mg/mL (500 mg/50 mL
  • Lyophilied powder for iv infusion: 100 mg
  • Lyophilized for injection: 500 mg

and 10 more forms; see the products table.

Registered products in the Philippines

60 products registered with the Food and Drug Administration (FDA) Philippines list Pemetrexed as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products60
Philippine FDA-registered products for Pemetrexed
Package insert
AlimtaPemetrexed (as disodium)
100 mg Powder for Concentrate for Solution for InfusionPh. Eur. Type I Clear Glass Vial in 10 mL (Box of 1's)
RxVAT-exempt
Vianex S.A. - Plant CGreece
ZUELLIG PHARMA CORPORATION
DR-XY35204
Dec 3, 2028
AlimtaPemetrexed (as disodium)
500 mg Powder for Concentrate for Solution for InfusionUSP Type I Clear and Colorless Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Vianex S.A. - Plant CGreece
Zuellig Pharma Corporation
DR-XY31536
Jun 7, 2028
BagoxedPemetrexed (as disodium hemipentahydrate)
500 mg Lyophilized Powder for Infusion (I.V.)USP Type 1 Clear and colorless glass vial (Box of 1 vial)
RxVAT-exempt
Laboratorio Kemex S.A.Argentine Republic
Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A.
DR-XY45722
Mar 6, 2032
CartrexedPemetrexed (as disodium)
100 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type I Borosilicate Glass Vial Sealed with Halogenated Butyl Rubber Stopper and Aluminum Plastic Cap x l's (Box of l’s)
RxVAT-exempt
Shanghai Chemo Wanbang Biopharma Co., Ltd.China
Sahar International Trading, Inc.
DR-XY47887
Mar 31, 2027
CartrexedPemetrexed (as disodium)
500 mg Lyophilized Powder for Injection. (IV Infusion)50-mL capacity Type I glass vial with halogenated butyl rubber stoper with aluminum-plastic cap (Box of 1's)
RxVAT-exempt
Shanghai Chemo Wanbang Biopharma Co. Ltd.China
Sahar International Trading Inc.
DR-XY48981
Jan 23, 2029
CartrexedPemetrexed (as disodium)
Lyophilized Powder for Injection 500 mg50-mL capacity Type I glass vial with halogenated butyl rubber stoper with aluminum-plastic cap (Box of 1's)
RxVAT-exempt
Shanghai Chemo Wanbang Biopharma Co. Ltd.China
Sahar International Trading Inc.
DRP-15020
Jan 23, 2029
Emipem-500Pemetrexed (as sodium)
500 mg Lyophilized Powder for In jection (I.V.)30 mL USP Type I clear glass vial with rubber stopper and sealed with orange flip-off seal (Box of 1 's)
RxVAT-exempt
Admac LifesciencesIndia
Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp.
DRP-14503-01
Sep 15, 2028
Meditrexed 100Pemetrexed(As disodium)
100 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type I glass vial with butyl rubber stopper, aluminum seal and green plastic flip-off cap. (Box of 1's)
RxVAT-exempt
Shanghai Chemo Wanbang Biopharma Co., Ltd.China
Medinova Pharmaceutical Inc.
DRP-13504
Feb 28, 2028
Meditrexed-500Pemetrexed (As disodium)
500mg Lyophilized Powder for Injection (IV Infusion)50 mL Type I glass vial with butyl rubber stopper, aluminum seal and olive green plastic flip-off cap (Box of 1's)
RxVAT-exempt
Shanghai Chemo Wanbang Biopharma Co., Ltd.China
Medinova Pharmaceutical Inc.
DRP-13503
Feb 28, 2028
Mevex 100Pemetrexed (as sodium)
100 mg Lyophilized Powder for Injection (IV)USP Type I clear and colorless glass vial sealed with 20 mm silicon plug bromo butyl rubber stopper and orange flip-off seal x 10 mL (Box of 1’s)
RxVAT-exempt
ADMAC LIFESCIENCESIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY46779
Dec 18, 2029
Mevex 500Pemetrexed (as Disodium)
500 mg Lyophilized for Injection (IV)30 mL USP Type I amber glass vial with orange coloured flip-off seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY45328
Apr 25, 2031
MixepremPemetrexed (as disodium)
500 mg Powder for Solution for IV Infusion30 mL-Capacity USP Type I Clear Glass Vial with BromoButyl Rubber Stopper and Orange colored Flip-Off Seal (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International Corporation
DRP-12473
Aug 16, 2032
Pemcord 100Pemetrexed (as disodium)
100mg Lyophilized Powder For Concentrate for Solution for Infusion (IV)Type I Clear Tubular Flat Glass Vial with Grey Silicon. Rubber Stopper and Aluminium Lavender Flip-Off Seal (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office
DR-XY46017
Nov 7, 2027
Pemcord 500Pemetrexed (as disodium)
500 mg Lyophilized Powder For Concentrate fo Solution for Infusion (IV)Type I Clear Tubular Glass Vial with Grey Silicon Rubber Stopper and Aluminium Royal Blue Flip-Off Royal-Blue Seal x 50 mL (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office
DR-XY46018
Sep 7, 2027
Pemcord-1000Pemetrexed (as disodium)
1g Lyophilized Powder For Solution For IV Infusion100 mL-capacity USP Type I Clear Glass Vial with grey silicon bromobutyl rubber stopper and royal blue aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch OfficeTrader: Accord Healthcare Pte. Ltd. - United Kingdom
DRP-11132
Feb 4, 2027
PemehopePemetrexed (as Disodium Hemipentahydrate)
100 mg Lyophilized Powder for Concentrate for Solution for Infusion (I.V.)15 mL USP Type I clear and colorless glass vial (Box of 1 vial)
RxVAT-exempt
Glenmark Generics S.A.Argentina
Glenmark Philippines, Inc.
DRP-8009
Oct 30, 2028
PemehopePemetrexed (as Disodium Hemipentahydrate)
500 mg Lyophilized Powder for Concentrate for Solution for Infusion (I.V.)30 mL USP Type I clear and colorless glass vial (Box of 1 vial)
RxVAT-exempt
Glenmark Generics S.A.Argentina
Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals, Ltd.
DRP-8010
Oct 31, 2028
PemestalPemetrexed (as disodium heptahydrate)
500 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I clear glass vial with 20 mm bromobutyl rubber stopper and 20 mm orange flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8996
Jul 29, 2030
Pemestal-100Pemetrexed (as disodium heptahydrate)
100 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I clear moulded glass vial Box of 1's
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8696
Feb 5, 2030
Pemeta-100Pemetrexed (as disodium heptahydrate)
100 mg Lyophilized Powder for Concentrate Solution. for IV Injection10 mL USP Type I Clear Glass Moulded Vial (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Orange Biotec Inc.
DRP-12659
Sep 19, 2027
Pemeta-500Pemetrexed (as disodium)
500 mg Powder for Concentrate Solution IV Infusion30 mL-capacity USP Type I glass vial with bromobutyl rubber stopper and orange colour flip of Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Orange Biotec Inc.
DRP-11134
Feb 4, 2027
PemexPemetrexed
100 mg Lyophilized Powder for Injection (IV)Type I Clear Borosilicate Glass with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 7 mL (Box of l’s) )
RxVAT-exempt
Jiangsu Hansoh Pharmaceutical Co., Ltd.China
Goodfellow Pharma Corporation
DR-XY47914
Apr 7, 2027
PemexPemetrexed (As Disodium)
500 mg Lyophilized Powder for Injection (IV)Type I Clear Borosilicate Glass with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 50 mL (Box of l's)
RxVAT-exempt
Jiangsu Hansoh Pharmaceutical Co., Ltd.China
Goodfellow Pharma Corporation
DR-XY47913
Apr 7, 2027
PemexbilPemetrexed (as disodium)
100 mg Lyophilized Powder for Intravenous (I.V.) Infusion20 mL clear USP Type I glass vial with grey bromobutyl rubber stopper, aluminum seal and grey flip-off cap (Box of 1’s)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon PharmaceuticalsTrader: Abil Chempharma Pvt. Ltd.
DR-XY48060
Jun 2, 2027
PemexbilPemetrexed
500 mg Lyophilized Powder for Intravenous (I.V.) Infusion50 mL clear USP Type 1 glass vial with grey bromobutyl rubber stopper, aluminum seal and grey flip off cap (Box of 1's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon PharmaceuticalsTrader: Abil Chempharma Pvt. Ltd.
DR-XY48059
May 30, 2027
Pemexed 500Pemetrexed (as disodium)
500 mg Lyophilized Powder for IV Infusion50 mL-capacity USP type I clear glass vial with grey chlorobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Gland Pharma LimitedIndia
Metro Drug, Inc.Trader: Mega Lifesciences (Australia) Pty Ltd.
DR-XY47607
Dec 14, 2026
PemiGetPemetrexed (as Disodium Heptahydrate)
100 mg Lyophilized Powder For Injection (IV)10 mL -capacity USP Type I Clear Glass Vial with Grey aluminum flip-off Seal (Box of 1's)
RxVAT-exempt
Beta Drugs LimitedIndia
2MG Incorporated
DRP-18281
Jun 4, 2031
PemiGetPemetrexed (as disodium heptahydrate)
500 mg Lyophilized Powder for Concentrate for Solution for IV Infusion30 mL-capacity USP Type I clear and colorless glass vial with grey butyl rubber plug and white color golden lacquered aluminum flip-off seal placed in a PVC tray (Box of 1's)
RxVAT-exempt
Beta Drugs LimitedIndia
2MG Incorporated
DRP-16608
May 15, 2030
PemirexPemetrexed (as disodium hemipentahydrate)
100 mg Lyophilized Powder for I.V. Infusion10 mL-capacity USP Type I Clear and Colorless Glass Vial with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Red Plastic Flip-Off Cap (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY44563
May 15, 2030
PemirexPemetrexed (As Disodium Hemipentahydrate)
300 mg Lyophilized Powder For IV InfusionUSP Type I Colorless Glass Vial (Box of 1's)
RxVAT-exempt
Korea United Pharin. Inc.korea
Qualimed Pharma, Inc.
DR-XY46097
Oct 12, 2027
PemirexPemetrexed (as disodium hemipentahydrate)
500 mg Lyophilized Powder for I.V. Infusion50 mL-capacity USP Type I Clear and Colorless Glass Vial with Gray Chlorobutyl Rubber Stopper and Aluminum Seal with Red Plastic Flip-Off Cap Box of 1's
RxVAT-exempt
Korea United Pharma Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY44315
Mar 11, 2030
Pemtero 100Pemetrexed (as disodium hemipentahydrate)
100 mg Lyophilied Powder for IV Infusion10 mL Type I clear molded glass vial with gray rubber stopper and purple aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Hetero Labs Limited (Unit VI)India
Camber Pharmaceuticals, Inc.
DRP-15505
Jul 30, 2029
Pemtero 500Pemetrexed (as disodium hemipentahydrate)
500 mg Lyophilized Powder for IV Infusion50 mL Type I clear glass vial with gray rubber stopper and purple aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Hetero Labs Limited (Unit VI)India
Camber Pharmaceuticals, Inc.
DRP-15504
Jul 30, 2029
PemtrexPemetrexed (as disodium hemipentahydrate)
10 mg/mL (500 mg/50 mL) Solution for Injection (IV Infusion)Type I Flint Clear Glass Vial Sealed with Dark Gray Chlorobutyl Rubber Stopper and Light Blue Aluminum Flip-Off Seal Cap x 50 mL (Box of 1's)
RxVAT-exempt
Shilpa Medicare Limited (Unit. 4, Pharmaceutical Formulations Sez)India
—
DR-XY48931
Nov 23, 2028
PermetrizzPemetrexed (as disodium)
500 mg Lyophilized Powder for Injection50-mL capacity Type I glass vial with halogenated butyl rubber stopper with aluminum-plastic cap (Box of 1's)
RxVAT-exempt
Shanghai Chemo Wanbang Biopharma Co. Ltd.China
Amson PharmaceuticalsImporter: Sahar International Trading Inc.
DRP-15020-01
Jan 23, 2029
Pexate 100Pemetrexed (as disodium)
100 mg Lyophilized Powder for Concentrate for Solution for Infusion (I.V.)USP Type I Clear Glass Vial with Gray Flip-off Seal (Box of 1's)
RxVAT-exempt
Naprod Lifesciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.
DRP-10579
May 27, 2028
Pexate 500Pemetrexed (as disodium)
500 mg Lyophilized Powder for Concentrate for Solution for Infusion (I.V.)USP Type I Clear Glass Vial with Gray Flip-off Seal (Box of 1's)
RxVAT-exempt
Napro Lifesciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.
DRP-10580
May 27, 2028
Pexitas 500Pemetrexed (as disodium heptahydrate)
500 mg Lyophilized Powder for Injection (IV Infusion)50 mL capacity Type I clear and colorless glass vial (Box of 1's)
RxVAT-exempt
Sun Pharmaceutical Industries Ltd.,India
SUN PHARMA PHILIPPINES, INC.
DRP-8827
Aug 22, 2029
PodoxredPemetrexed (as disodium)
100 mg Lyophilized Powder for Injection (IV Infusion)10 mL-capacity USP Type 1 clear tubular glass vial with gray bromobutyl rubber stopper and aluminum flip-off seal Box of 1's
RxVAT-exempt
Dr. Reddy's Laboratories Ltd. (Formulation Unit 7)India
GLOBO ASIATICO ENTERPRISES, INC.
DR-XY46621
Jun 27, 2029
PodoxredPemetrexed (as Disodium)
500 mg Lyophilized Powder for Injection (IV Infusion)50 mL-Capacity USP Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's)
RxVAT-exempt
Dr. Reddy's Laboratories Ltd. (Formulation Unit 7)India
Globo Asiatico Enterprises, Inc.
DR-XY46622
Jun 27, 2029
Prexvid 100Pemetrexed (as disodium hemipentahydrate)
100 mg Powder for Concentrate for Solution for Infusion (I.V.)10 mL Type I glass vial with brominated butyl rubber stopper and blue aluminum-plastic cap (Box of 1's)
RxVAT-exempt
Qilu Pharmaceutical Hainan Co., Ltd.China
Hovid Inc.Trader: Hovid Bhd.
DRP-14635
Nov 8, 2028
Prexvid 500Pemetrexed (as disodium hemipentahydrate)
500mg Powder for Concentrate for Solution for Infusion (I.V.)50 mL Type I glass vial with brominated butyl rubber stopper and blue aluminum cap (Box of 1's)
RxVAT-exempt
Qilu Pharmaceutical Hainan Co., Ltd.China
Hovid Inc.Trader: Hovid Bhd.
DRP-11436
Mar 15, 2027
Prixanep-100Pemetrexed (as disodium hemipentahydrate)
100 mg Lyophilized Powder for Intravenous InfusionUSP Type I glass vial with a grey bromo butyl stopper and an aluminum seal with a grey cap (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-8697
Feb 5, 2030
Prixanep-500Pemetrexed (as disodium hemipentahydrate)
500 mg Lyophilized Powder for Intravenous InfusionUSP Type I glass vial with a grey bromo butyl stopper and an aluminum seal with a grey cap (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-8698
Feb 5, 2030
Rixanep-100Pemetrexed (as disodium hemipentahydrate)
100 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I glass vial with grey bromo butyl stopper and an aluminum flip off grey color seal (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Ambica International Corporation
DRP-8995
Mar 12, 2037
Rixanep-500Pemetrexed (as disodium)
500 mg Lyophilized Powder for Injection (IV Infusion)USP Type I Glass Vial x 50 mL w/ grey bromobutyl double slotted lyophilised stopper and aluminum grey flip-off seal (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Ambica International Corporation
DRP-9787
Sep 3, 2031
Saphmetrex-500Pemetrexed (as disodium)
500mg Lyophilized Powder for IV InfusionUSP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal, and flip-off cap
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-18519
Jul 27, 2031
Saphmetrex1Pemetrexed (as disodium)
1 g Lyophilized Powder for IV InfusionUSP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal, and flip-off cap (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-18518
Jul 27, 2031
Saphmetrex100Pemetrexed (as disodium)
100 mg Lyophilized Powder for IV InfusionUSP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal, and flip-off cap
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-18520
Jul 27, 2031
Startrex 100Pemetrexed (as disodium heptahydrate)
100 mg Lyophilized Powder for Injection (I. V. Infusion)
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-17609
Feb 19, 2031
Startrex 500Pemetrexed (as disodium)
500 mg Lyophilized Powder for Injection (I.V.)30 mL USP Type I clear glass vial with rubber stopper and sealed with orange flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-14503
Sep 15, 2028
TrekalPemetrexed (as disodium hemipentahydrate)
500 mg Lyophilized Powder for Intravenous InfusionType I Colourless Glass Vial with Bromobutyl Rubber Stopper, Aluminum Crimp Cap, and Bordeaux Plastic Flip Cap (Box of 1's)
RxVAT-exempt
Eriochem S.A.Argentina
GLOBO ASIATICO ENT. INC
DR-XY46435
Oct 10, 2028
Trepexed-100Pemetrexed (as disodium heptahydrate)
100 mg Lyophilized Powder for IV Infusion10 mL USP Type I vial with grey bromobutyl rubber stopper, aluminum seal, and orange flip-off cap (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
AGB Pharmaceutical Trading and CorporationImporter: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-14557
Oct 13, 2028
Trepexed-500Pemetrexed (as disodium)
500mg Lyophilized Powder for IV InfusionBox of 1 contains: 30 mL Capacity USP Type I Clear Glass Vial with Grey Bromo Butyl Rubber Stopper and Orange colored Flip-Off Seal
RxVAT-exempt
Admac LifesciencesIndia
AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Health sciences Pvt. Ltd.
DRP-12922
Oct 28, 2027
TrexedPemetrexed (as disodium heptahydrate)
100 mg Lyophilized Powder for Injection for IV InfusionUSP Type I clear moulded glass vial (Box of 1’s)
RxVAT-exempt
ADMAC LifesciencesIndia
Unilab, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8696-01
Feb 5, 2030
TrexedPemetrexed (as disodium heptahydrate)
500 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I clear glass vial with 20 mm bromobutyl rubber stopper and 20 mm orange flip-off seal (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Unilab, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8996-01
Jul 29, 2030
Trexifar 500Pemetrexed (as disodium heptahydrate)
500 mg Lyophilized Powder for Solution for Injection (IV)In a box with PP white tray, 15 mL-capacity type I clear glass vial with rubber stopper and plastic white flip-off plastic seal (Box of 1's)
RxVAT-exempt
Eskayef Pharmaceuticals Limited Rupganj PlantBangladesh
Pharmakon Biotec Inc.
DRP-18726
Aug 27, 2031
TrexorPemetrexed (as disodium hemipentahydrate)
100 mg Lyophilized Powder for Intravenous InfusionUSP Type I clear glass vial Box of 1's
RxVAT-exempt
Ildong Pharmaceutical Co., Ltd.Republic of Korea
International Apex Pharmaceutical Co., Ltd.
DR-XY46611
Jun 7, 2029
TrexorPemetrexed (as disodium hemipentahydrate)
500 mg Lyophilized Powder for Intravenous InfusionUSP Type I clear glass vial (Box of 1's)
RxVAT-exempt
Ildong Pharmaceutical Co., Ltd.Republic of Korea
International Apex Pharmaceuticals, Inc.
DR-XY46610
Jun 7, 2029
(no brand name)Pemetrexed (as disodium hemipentahydrate)
500 mg Lyophilized Powder for IV Injection50 mL USP Type I Tubular Glass Vial with 20 mm Grey Butyl Rubber Stopper and Aluminum Flip-off Seal (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49228
Sep 24, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS For injection: 100 mg or 500 mg pemetrexed as a white to light-yellow or green-yellow lyophilized powder in single-dose vials for reconstitution. For Injection: 100 mg or 500 mg lyophilized powder in single-dose vial (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Myelosuppression: Can cause severe bone marrow suppression resulting in cytopenia and an increased risk of infection. Do not administer ALIMTA when the absolute neutrophil count is less than 1500 cells/mm 3 and platelets are less than 100,000 cells/mm 3. Initiate supplementation with oral folic acid and intramuscular vitamin B12 to reduce the severity of hematologic and gastrointestinal toxicity of ALIMTA. (2.4, 5.1)
  • Renal Failure: Can cause severe, and sometimes fatal, renal failure. Do not administer when creatinine clearance is less than 45 mL/min. (2.3, 5.2)
  • Bullous and Exfoliative Skin Toxicity: Permanently discontinue for severe and life-threatening bullous, blistering or exfoliating skin toxicity. (5.3)
  • Interstitial Pneumonitis: Withhold for acute onset of new or progressive unexplained pulmonary symptoms. Permanently discontinue if pneumonitis is confirmed. (5.4)
  • Radiation Recall: Can occur in patients who received radiation weeks to years previously; permanently discontinue for signs of radiation recall. (5.5)
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (5.7, 8.1, 8.3)
5.1 Myelosuppression and Increased Risk

5.1 Myelosuppression and Increased Risk of Myelosuppression without Vitamin Supplementation ALIMTA can cause severe myelosuppression resulting in a requirement for transfusions and which may lead to neutropenic infection. The risk of myelosuppression is increased in patients who do not receive vitamin supplementation. In Study JMCH, incidences of Grade 3-4 neutropenia (38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received ALIMTA plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B12 prior to and throughout ALIMTA plus cisplatin treatment.

Initiate supplementation with oral folic acid and intramuscular vitamin B12 prior to the first dose of ALIMTA; continue vitamin supplementation during treatment and for 21 days after the last dose of ALIMTA to reduce the severity of hematologic and gastrointestinal toxicity of ALIMTA [see Dosage and Administration (2.4)]. Obtain a complete blood count at the beginning of each cycle.

Do not administer ALIMTA until the ANC is at least 1500 cells/mm 3 and platelet count is at least 100,000 cells/mm 3. Permanently reduce ALIMTA in patients with an ANC of less than 500 cells/mm 3 or platelet count of less than 50,000 cells/mm 3 in previous cycles [see Dosage and Administration (2.6)]. In Studies JMDB and JMCH, among patients who received vitamin supplementation, incidence of Grade 3-4 neutropenia was 15% and 23%, the incidence of Grade 3-4 anemia was 6% and 4%, and incidence of Grade 3-4 thrombocytopenia was 4% and 5%, respectively.

In Study JMCH, 18% of patients in the ALIMTA arm required red blood cell transfusions compared to 7% of patients in the cisplatin arm [see Adverse Reactions (6.1)]. In Studies JMEN, PARAMOUNT, and JMEI, where all patients received vitamin supplementation, incidence of Grade 3-4 neutropenia ranged from 3% to 5%, and incidence of Grade 3-4 anemia ranged from 3% to 5%.

5.2 Renal Failure

5.2 Renal Failure ALIMTA can cause severe, and sometimes fatal, renal toxicity. The incidences of renal failure in clinical studies in which patients received ALIMTA with cisplatin were: 2.1% in Study JMDB and 2.2% in Study JMCH. The incidence of renal failure in clinical studies in which patients received ALIMTA as a single agent ranged from 0.4% to 0.6% (Studies JMEN, PARAMOUNT, and JMEI [see Adverse Reactions (6.1)].

Determine creatinine clearance before each dose and periodically monitor renal function during treatment with ALIMTA. Withhold ALIMTA in patients with a creatinine clearance of less than 45 mL/minute [see Dosage and Administration (2.3)].

5.3 Bullous and Exfoliative Skin Toxicity

5.3 Bullous and Exfoliative Skin Toxicity Serious and sometimes fatal, bullous, blistering and exfoliative skin toxicity, including cases suggestive of Stevens-Johnson Syndrome/Toxic epidermal necrolysis can occur with ALIMTA. Permanently discontinue ALIMTA for severe and life-threatening bullous, blistering or exfoliating skin toxicity.

5.4 Interstitial Pneumonitis

5.4 Interstitial Pneumonitis Serious interstitial pneumonitis, including fatal cases, can occur with ALIMTA treatment. Withhold ALIMTA for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, or fever pending diagnostic evaluation. If pneumonitis is confirmed, permanently discontinue ALIMTA.

5.5 Radiation Recall

5.5 Radiation Recall Radiation recall can occur with ALIMTA in patients who have received radiation weeks to years previously. Monitor patients for inflammation or blistering in areas of previous radiation treatment. Permanently discontinue ALIMTA for signs of radiation recall.

5.6 Increased Risk of Toxicity with Ibuprofen in Patients with Renal Impairment Exposure

5.6 Increased Risk of Toxicity with Ibuprofen in Patients with Renal Impairment Exposure to ALIMTA is increased in patients with mild to moderate renal impairment who take concomitant ibuprofen, increasing the risks of adverse reactions of ALIMTA. In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of ALIMTA.

If concomitant ibuprofen use cannot be avoided, monitor patients more frequently for ALIMTA adverse reactions, including myelosuppression, renal, and gastrointestinal toxicity [see Dosage and Administration (2.5), Drug Interactions (7), and Clinical Pharmacology (12.3)].

5.7 Embryo-Fetal Toxicity

5.7 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, ALIMTA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, intravenous administration of pemetrexed to pregnant mice during the period of organogenesis was teratogenic, resulting in developmental delays and increased malformations at doses lower than the recommended human dose of 500 mg/m 2.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ALIMTA and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALIMTA and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Ibuprofen increased risk of ALIMTA toxicity in patients with mild to moderate renal impairment. Modify the ibuprofen dosage as recommended for patients with a creatinine clearance between 45 mL/min and 79 mL/min. (2.5, 5.6, 7) Effects of Ibuprofen on Pemetrexed Ibuprofen increases exposure (AUC) of pemetrexed [see Clinical Pharmacology (12.3)].

In patients with creatinine clearance between 45 mL/min and 79 mL/min: Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of ALIMTA [see Dosage and Administration (2.5)]. Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant administration of ibuprofen cannot be avoided.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies indicated that pemetrexed is a substrate of OAT3 (organic anion transporter 3), a transporter that is involved in the active secretion of pemetrexed.

Drug Interaction Studies Drugs Inhibiting OAT3 Transporter Ibuprofen, an OAT3 inhibitor, administered at 400 mg four times a day decreased the clearance of pemetrexed and increased its exposure (AUC) by approximately 20% in patients with normal renal function (creatinine clearance >80 mL/min).

In Vitro Studies Pemetrexed is a substrate for OAT3.

Ibuprofen, an OAT3 inhibitor inhibited the uptake of pemetrexed in OAT3-expressing cell cultures with an average [I u ]/IC 50 ratio of 0.38.

In vitro data predict that at clinically relevant concentrations, other NSAIDs (naproxen, diclofenac, celecoxib) would not inhibit the uptake of pemetrexed by OAT3 and would not increase the AUC of pemetrexed to a clinically significant extent.

Pemetrexed is a substrate for OAT4.

In vitro, ibuprofen and other NSAIDs (naproxen, diclofenac, celecoxib) are not inhibitors of OAT4 at clinically relevant concentrations.

Drugs Metabolized by Cytochrome P450 Enzymes In vitro studies suggest that pemetrexed does not inhibit the clearance of drugs metabolized by CYP3A, CYP2D6, CYP2C9, and CYP1A2.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following adverse reactions are discussed in greater detail in other sections of the labeling: Myelosuppression [see Warnings and Precautions (5.1)] Renal failure [see Warnings and Precautions (5.2)] Bullous and exfoliative skin toxicity [see Warning and Precautions (5.3)] Interstitial pneumonitis [see Warnings and Precautions (5.4)] Radiation recall [see Warnings and Precautions (5.5)] The most common adverse reactions (incidence ≥20%) of ALIMTA, when administered as a single agent are fatigue, nausea, and anorexia. (6.1)
  • The most common adverse reactions (incidence ≥20%) of ALIMTA when administered with cisplatin are vomiting, neutropenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation. (6.1)
  • The most common adverse reactions (incidence ≥20%) of ALIMTA when administered in combination with pembrolizumab and platinum chemotherapy are fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, and pyrexia. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice. In clinical trials, the most common adverse reactions (incidence ≥20%) of ALIMTA, when administered as a single agent, are fatigue, nausea, and anorexia.

The most common adverse reactions (incidence ≥20%) of ALIMTA, when administered in combination with cisplatin are vomiting, neutropenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation. The most common adverse reactions (incidence ≥20%) of ALIMTA, when administered in combination with pembrolizumab and platinum chemotherapy, are fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, and pyrexia.

Non-Squamous NSCLC First-line Treatment of Metastatic Non-squamous NSCLC with Pembrolizumab and Platinum Chemotherapy The safety of ALIMTA, in combination with pembrolizumab and investigator's choice of platinum (either carboplatin or cisplatin), was investigated in Study KEYNOTE-189, a multicenter, double-blind, randomized (2:1), active-controlled trial in patients with previously untreated, metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. A total of 607 patients received ALIMTA, pembrolizumab, and platinum every 3 weeks for 4 cycles followed by ALIMTA and pembrolizumab (n=405), or placebo, ALIMTA, and platinum every 3 weeks for 4 cycles followed by placebo and ALIMTA (n=202).

Patients with autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks were ineligible [see Clinical Studies (14.1)]. The median duration of exposure to ALIMTA was 7.2 months (range: 1 day to 1.7 years).

Seventy-two percent of patients received carboplatin. The study population characteristics were: median age of 64 years (range: 34 to 84), 49% age 65 years or older, 59% male, 94% White and 3% Asian, and 18% with history of brain metastases at baseline. ALIMTA was discontinued for adverse reactions in 23% of patients in the ALIMTA, pembrolizumab, and platinum arm.

The most common adverse reactions resulting in discontinuation of ALIMTA in this arm were acute kidney injury (3%) and pneumonitis (2%). Adverse reactions leading to interruption of ALIMTA occurred in 49% of patients in the ALIMTA, pembrolizumab, and platinum arm. The most common adverse reactions or laboratory abnormalities leading to interruption of ALIMTA in this arm (≥2%) were neutropenia (12%), anemia (7%), asthenia (4%), pneumonia (4%), thrombocytopenia (4%), increased blood creatinine (3%), diarrhea (3%), and fatigue (3%).

Table 2 summarizes the adverse reactions that occurred in ≥20% of patients treated with ALIMTA, pembrolizumab, and platinum. Table 2: Adverse Reactions Occurring in ≥20% of Patients in KEYNOTE-189 a Graded per NCI CTCAE version 4.03. b Includes asthenia and fatigue. c Includes genital rash, rash, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, and rash pustular.

ALIMTA Pembrolizumab Platinum Chemotherapy n=405 Placebo ALIMTA Platinum Chemotherapy n=202 Adverse Reaction All Grades a (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) Gastrointestinal Disorders Nausea 56 3.5 52 3.5 Constipation 35 1.0 32 0.5 Diarrhea 31 5 21 3.0 Vomiting 24 3.7 23 3.0 General Disorders and Administration Site Conditions Fatigue b 56 12 58 6 Pyrexia 20 0.2 15 0 Metabolism and Nutrition Disorders Decreased appetite 28 1.5 30 0.5 Skin and Subcutaneous Tissue Disorders Rash c 25 2.0 17 2.5 Respiratory, Thoracic and Mediastinal Disorders Cough 21 0 28 0 Dyspnea 21 3.7 26 5 Table 3 summarizes the laboratory abnormalities that worsened from baseline in at least 20% of patients treated with ALIMTA, pembrolizumab, and platinum. Table 3: Laboratory Abnormalities Worsened from Baseline in ≥20% of Patients in KEYNOTE-189 a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: ALIMTA/pembrolizumab/platinum chemotherapy (range: 381 to 401 patients) and placebo/ALIMTA/platinum chemotherapy (range: 184 to 197 patients). b Graded per NCI CTCAE version 4.03.

ALIMTA Pembrolizumab Platinum Chemotherapy Placebo ALIMTA Platinum Chemotherapy Laboratory Test a All Grades b % Grades 3-4 % All Grades % Grades 3-4 % Chemistry Hyperglycemia 63 9 60 7 Increased ALT 47 3.8 42 2.6 Increased AST 47 2.8 40 1.0 Hypoalbuminemia 39 2.8 39 1.1 Increased creatinine 37 4.2 25 1.0 Hyponatremia 32 7 23 6 Hypophosphatemia 30 10 28 14 Increased alkaline phosphatase 26 1.8 29 2.1 Hypocalcemia 24 2.8 17 0.5 Hyperkalemia 24 2.8 19 3.1 Hypokalemia 21 5 20 5 Hematology Anemia 85 17 81 18 Lymphopenia 64 22 64 25 Neutropenia 48 20 41 19 Thrombocytopenia 30 12 29 8 Initial Treatment in Combination with Cisplatin The safety of ALIMTA was evaluated in Study JMDB, a randomized (1:1), open-label, multicenter trial conducted in chemotherapy-naive patients with locally advanced or metastatic NSCLC. Patients received either ALIMTA 500 mg/m 2 intravenously and cisplatin 75 mg/m 2 intravenously on Day 1 of each 21-day cycle (n=839) or gemcitabine 1250 mg/m 2 intravenously on Days 1 and 8 and cisplatin 75 mg/m 2 intravenously on Day 1 of each 21-day cycle (n=830).

All patients were fully supplemented with folic acid and vitamin B12. Study JMDB excluded patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS of 2 or greater), uncontrolled third-space fluid retention, inadequate bone marrow reserve and organ function, or a calculated creatinine clearance less than 45 mL/min.

Patients unable to stop using aspirin or other non-steroidal anti-inflammatory drugs or unable to take folic acid, vitamin B12 or corticosteroids were also excluded from the study. The data described below reflect exposure to ALIMTA plus cisplatin in 839 patients in Study JMDB. Median age was 61 years (range 26-83 years); 70% of patients were men; 78% were White, 16% were Asian, 2.9% were Hispanic or Latino, 2.1% were Black or African American, and <1% were other ethnicities; 36% had an ECOG PS 0.

Patients received a median of 5 cycles of ALIMTA. Table 4 provides the frequency and severity of adverse reactions that occurred in ≥5% of 839 patients receiving ALIMTA in combination with cisplatin in Study JMDB. Study JMDB was not designed to demonstrate a statistically significant reduction in adverse reaction rates for ALIMTA, as compared to the control arm, for any specified adverse reaction listed in Table 4.

Table 4: Adverse Reactions Occurring in ≥5% of Fully Vitamin-Supplemented Patients Receiving ALIMTA in Combination with Cisplatin Chemotherapy in Study JMDB a NCI CTCAE version 2.0. Adverse Reaction a ALIMTA/Cisplatin (N=839) Gemcitabine/Cisplatin (N=830) All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) All adverse reactions 90 37 91 53 Laboratory Hematologic Anemia 33 6 46 10 Neutropenia 29 15 38 27 Thrombocytopenia 10 4 27 13 Renal Elevated creatinine 10 1 7 1 Clinical Constitutional symptoms Fatigue 43 7 45 5 Gastrointestinal Nausea 56 7 53 4 Vomiting 40 6 36 6 Anorexia 27 2 24 1 Constipation 21 1 20 0 Stomatitis/pharyngitis 14 1 12 0 Diarrhea 12 1 13 2 Dyspepsia/heartburn 5 0 6 0 Neurology Sensory neuropathy 9 0 12 1 Taste disturbance 8 0 9 0 Dermatology/Skin Alopecia 12 0 21 1 Rash/Desquamation 7 0 8 1 The following additional adverse reactions of ALIMTA were observed.

Incidence 1% to <5% Body as a Whole — febrile neutropenia, infection, pyrexia General Disorders — dehydration Metabolism and Nutrition — increased AST, increased ALT Renal —renal failure Eye Disorder — conjunctivitis Incidence <1% Cardiovascular — arrhythmia General Disorders — chest pain Metabolism and Nutrition — increased GGT Neurology — motor neuropathy Maintenance Treatment Following First-line Non-ALIMTA Containing Platinum-Based Chemotherapy In Study JMEN, the safety of ALIMTA was evaluated in a randomized (2:1), placebo-controlled, multicenter trial conducted in patients with non-progressive locally advanced or metastatic NSCLC following four cycles of a first-line, platinum-based chemotherapy regimen. Patients received either ALIMTA 500 mg/m 2 or matching placebo intravenously every 21 days until disease progression or unacceptable toxicity.

Patients in both study arms were fully supplemented with folic acid and vitamin B12. Study JMEN excluded patients with an ECOG PS of 2 or greater, uncontrolled third-space fluid retention, inadequate bone marrow reserve and organ function, or a calculated creatinine clearance less than 45 mL/min. Patients unable to stop using aspirin or other non-steroidal anti-inflammatory drugs or unable to take folic acid, vitamin B12 or corticosteroids were also excluded from the study.

The data described below reflect exposure to ALIMTA in 438 patients in Study JMEN. Median age was 61 years (range 26-83 years), 73% of patients were men; 65% were White, 31% were Asian, 2.9% were Hispanic or Latino, and <2% were other ethnicities; 39% had an ECOG PS 0. Patients received a median of 5 cycles of ALIMTA and a relative dose intensity of ALIMTA of 96%.

Approximately half the patients (48%) completed at least six, 21-day cycles and 23% completed ten or more 21-day cycles of ALIMTA. Table 5 provides the frequency and severity of adverse reactions reported in ≥5% of the 438 ALIMTA-treated patients in Study JMEN. Table 5: Adverse Reactions Occurring in ≥5% of Patients Receiving ALIMTA in Study JMEN a NCI CTCAE version 3.0.

Adverse Reaction a ALIMTA (N=438) Placebo (N=218) All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) All adverse reactions 66 16 37 4 Laboratory Hematologic Anemia 15 3 6 1 Neutropenia 6 3 0 0 Hepatic Increased ALT 10 0 4 0 Increased AST 8 0 4 0 Clinical Constitutional symptoms Fatigue 25 5 11 1 Gastrointestinal Nausea 19 1 6 1 Anorexia 19 2 5 0 Vomiting 9 0 1 0 Mucositis/stomatitis 7 1 2 0 Diarrhea 5 1 3 0 Infection 5 2 2 0 Neurology Sensory neuropathy 9 1 4 0 Dermatology/Skin Rash/desquamation 10 0 3 0 The requirement for transfusions (9.5% versus 3.2%), primarily red blood cell transfusions, and for erythropoiesis stimulating agents (5.9% versus 1.8%) were higher in the ALIMTA arm compared to the placebo arm. The following additional adverse reactions were observed in patients who received ALIMTA.

Incidence 1% to<5% Dermatology/Skin — alopecia, pruritus/itching Gastrointestinal — constipation General Disorders — edema, fever Hematologic — thrombocytopenia Eye Disorder — ocular surface disease (including conjunctivitis), increased lacrimation Incidence <1% Cardiovascular — supraventricular arrhythmia Dermatology/Skin — erythema multiforme General Disorders — febrile neutropenia, allergic reaction/hypersensitivity Neurology — motor neuropathy Renal — renal failure Maintenance Treatment Following First-line ALIMTA Plus Platinum Chemotherapy The safety of ALIMTA was evaluated in PARAMOUNT, a randomized (2:1), placebo-controlled study conducted in patients with non-squamous NSCLC with non-progressive (stable or responding disease) locally advanced or metastatic NSCLC following four cycles of ALIMTA in combination with cisplatin as first-line therapy for NSCLC. Patients were randomized to receive ALIMTA 500 mg/m 2 or matching placebo intravenously on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.

Patients in both study arms received folic acid and vitamin B12 supplementation. PARAMOUNT excluded patients with an ECOG PS of 2 or greater, uncontrolled third-space fluid retention, inadequate bone marrow reserve and organ function, or a calculated creatinine clearance less than 45 mL/min. Patients unable to stop using aspirin or other non-steroidal anti-inflammatory drugs or unable to take folic acid, vitamin B12 or corticosteroids were also excluded from the study.

The data described below reflect exposure to ALIMTA in 333 patients in PARAMOUNT. Median age was 61 years (range 32 to 83 years); 58% of patients were men; 94% were White, 4.8% were Asian, and <1% were Black or African American; 36% had an ECOG PS 0. The median number of maintenance cycles was 4 for ALIMTA and placebo arms.

Dose reductions for adverse reactions occurred in 3.3% of patients in the ALIMTA arm and 0.6% in the placebo arm. Dose delays for adverse reactions occurred in 22% of patients in the ALIMTA arm and 16% in the placebo arm. Table 6 provides the frequency and severity of adverse reactions reported in ≥5% of the 333 ALIMTA-treated patients in PARAMOUNT.

Table 6: Adverse Reactions Occurring in ≥5% of Patients Receiving ALIMTA in PARAMOUNT a NCI CTCAE version 3.0. Adverse Reaction a ALIMTA (N=333) Placebo (N=167) All Grades (%) Grade 3-4 (%) All Grades (%) Grades 3-4 (%) All adverse reactions 53 17 34 4.8 Laboratory Hematologic Anemia 15 4.8 4.8 0.6 Neutropenia 9 3.9 0.6 0 Clinical Constitutional symptoms Fatigue 18 4.5 11 0.6 Gastrointestinal Nausea 12 0.3 2.4 0 Vomiting 6 0 1.8 0 Mucositis/stomatitis 5 0.3 2.4 0 General disorders Edema 5 0 3.6 0 The requirement for red blood cell (13% versus 4.8%) and platelet (1.5% versus 0.6%) transfusions, erythropoiesis stimulating agents (12% versus 7%), and granulocyte colony stimulating factors (6% versus 0%) were higher in the ALIMTA arm compared to the placebo arm.

The following additional Grade 3 or 4 adverse reactions were observed more frequently in the ALIMTA arm.

Incidence 1% to <5% Blood/Bone Marrow — thrombocytopenia General Disorders — febrile neutropenia Incidence <1% Cardiovascular — ventricular tachycardia, syncope General Disorders — pain Gastrointestinal — gastrointestinal obstruction Neurologic — depression Renal — renal failure Vascular — pulmonary embolism Treatment of Recurrent Disease After Prior Chemotherapy The safety of ALIMTA was evaluated in Study JMEI, a randomized (1:1), open-label, active-controlled trial conducted in patients who had progressed following platinum-based chemotherapy. Patients received ALIMTA 500 mg/m 2 intravenously or docetaxel 75 mg/m 2 intravenously on Day 1 of each 21-day cycle.

All patients on the ALIMTA arm received folic acid and vitamin B12 supplementation. Study JMEI excluded patients with an ECOG PS of 3 or greater, uncontrolled third-space fluid retention, inadequate bone marrow reserve and organ function, or a calculated creatinine clearance less than 45 mL/min. Patients unable to discontinue aspirin or other non-steroidal anti-inflammatory drugs or unable to take folic acid, vitamin B12 or corticosteroids were also excluded from the study.

The data described below reflect exposure to ALIMTA in 265 patients in Study JMEI. Median age was 58 years (range 22 to 87 years); 73% of patients were men; 70% were White, 24% were Asian, 2.6% were Black or African American, 1.8% were Hispanic or Latino, and <2% were other ethnicities; 19% had an ECOG PS 0. Table 7 provides the frequency and severity of adverse reactions reported in ≥5% of the 265 ALIMTA-treated patients in Study JMEI.

Study JMEI is not designed to demonstrate a statistically significant reduction in adverse reaction rates for ALIMTA, as compared to the control arm, for any specified adverse reaction listed in the Table 7 below. Table 7: Adverse Reactions Occurring in ≥5% of Fully Supplemented Patients Receiving ALIMTA in Study JMEI a NCI CTCAE version 2.0.

Adverse Reaction a ALIMTA (N=265) Docetaxel (N=276) All Grades (%) Grades 3-4 (%) All Grade (%) Grades 3-4 (%) Laboratory Hematologic Anemia 19 4 22 4 Neutropenia 11 5 45 40 Thrombocytopenia 8 2 1 0 Hepatic Increased ALT 8 2 1 0 Increased AST 7 1 1 0 Clinical Gastrointestinal Nausea 31 3 17 2 Anorexia 22 2 24 3 Vomiting 16 2 12 1 Stomatitis/pharyngitis 15 1 17 1 Diarrhea 13 0 24 3 Constipation 6 0 4 0 Constitutional symptoms Fatigue 34 5 36 5 Fever 8 0 8 0 Dermatology/Skin Rash/desquamation 14 0 6 0 Pruritus 7 0 2 0 Alopecia 6 1 38 2 The following additional adverse reactions were observed in patients assigned to receive ALIMTA.

Incidence 1% to <5% Body as a Whole — abdominal pain, allergic reaction/hypersensitivity, febrile neutropenia, infection Dermatology/Skin — erythema multiforme Neurology — motor neuropathy, sensory neuropathy Incidence <1% Cardiovascular — supraventricular arrhythmias Renal — renal failure Mesothelioma The safety of ALIMTA was evaluated in Study JMCH, a randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy for MPM. Patients received ALIMTA 500 mg/m 2 intravenously in combination with cisplatin 75 mg/m 2 intravenously on Day 1 of each 21-day cycle or cisplatin 75 mg/m 2 intravenously on Day 1 of each 21-day cycle administered until disease progression or unacceptable toxicity.

Safety was assessed in 226 patients who received at least one dose of ALIMTA in combination with cisplatin and 222 patients who received at least one dose of cisplatin alone. Among 226 patients who received ALIMTA in combination with cisplatin, 74% (n=168) received full supplementation with folic acid and vitamin B12 during study therapy, 14% (n=32) were never supplemented, and 12% (n=26) were partially supplemented.

Study JMCH excluded patients with Karnofsky Performance Scale (KPS) of less than 70, inadequate bone marrow reserve and organ function, or a calculated creatinine clearance less than 45 mL/min. Patients unable to stop using aspirin or other non-steroidal anti-inflammatory drugs were also excluded from the study. The data described below reflect exposure to ALIMTA in 168 patients that were fully supplemented with folic acid and vitamin B12.

Median age was 60 years (range 19 to 85 years); 82% were men; 92% were White, 5% were Hispanic or Latino, 3.0% were Asian, and <1% were other ethnicities; 54% had KPS of 90-100. The median number of treatment cycles administered was 6 in the ALIMTA/cisplatin fully supplemented group and 2 in the ALIMTA/cisplatin never supplemented group.

Patients receiving ALIMTA in the fully supplemented group had a relative dose intensity of 93% of the protocol-specified ALIMTA dose intensity. The most common adverse reaction resulting in dose delay was neutropenia. Table 8 provides the frequency and severity of adverse reactions ≥5% in the subgroup of ALIMTA-treated patients who were fully vitamin supplemented in Study JMCH.

Study JMCH was not designed to demonstrate a statistically significant reduction in adverse reaction rates for ALIMTA, as compared to the control arm, for any specified adverse reaction listed in the table below. Table 8: Adverse Reactions Occurring in ≥5% of Fully Supplemented Subgroup of Patients Receiving ALIMTA/Cisplatin in Study JMCH a a In Study JMCH, 226 patients received at least one dose of ALIMTA in combination with cisplatin and 222 patients received at least one dose of cisplatin.

Table 8 provides the ADRs for subgroup of patients treated with ALIMTA in combination with cisplatin (168 patients) or cisplatin alone (163 patients) who received full supplementation with folic acid and vitamin B12 during study therapy. b NCI CTCAE version 2.0. Adverse Reaction b ALIMTA/cisplatin (N=168) Cisplatin (N=163) All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) Laboratory Hematologic Neutropenia 56 23 13 3 Anemia 26 4 10 0 Thrombocytopenia 23 5 9 0 Renal Elevated creatinine 11 1 10 1 Decreased creatinine clearance 16 1 18 2 Clinical Eye Disorder Conjunctivitis 5 0 1 0 Gastrointestinal Nausea 82 12 77 6 Vomiting 57 11 50 4 Stomatitis/pharyngitis 23 3 6 0 Anorexia 20 1 14 1 Diarrhea 17 4 8 0 Constipation 12 1 7 1 Dyspepsia 5 1 1 0 Constitutional Symptoms Fatigue 48 10 42 9 Metabolism and Nutrition Dehydration 7 4 1 1 Neurology Sensory neuropathy 10 0 10 1 Taste disturbance 8 0 6 0 Dermatology/Skin Rash 16 1 5 0 Alopecia 11 0 6 0 The following additional adverse reactions were observed in patients receiving ALIMTA plus cisplatin: Incidence 1% to <5% Body as a Whole — febrile neutropenia, infection, pyrexia Dermatology/Skin — urticaria General Disorders — chest pain Metabolism and Nutrition — increased AST, increased ALT, increased GGT Renal — renal failure Incidence <1% Cardiovascular — arrhythmia Neurology — motor neuropathy Exploratory Subgroup Analyses based on Vitamin Supplementation Table 9 provides the results of exploratory analyses of the frequency and severity of NCI CTCAE Grade 3 or 4 adverse reactions reported in more ALIMTA-treated patients who did not receive vitamin supplementation (never supplemented) as compared with those who received vitamin supplementation with daily folic acid and vitamin B12 from the time of enrollment in Study JMCH (fully-supplemented).

Table 9: Exploratory Subgroup Analysis of Selected Grade 3/4 Adverse Reactions Occurring in Patients Receiving ALIMTA in Combination with Cisplatin with or without Full Vitamin Supplementation in Study JMCH a a NCI CTCAE version 2.0. Grade 3-4 Adverse Reactions Fully Supplemented Patients N=168 (%) Never Supplemented Patients N=32 (%) Neutropenia 23 38 Thrombocytopenia 5 9 Vomiting 11 31 Febrile neutropenia 1 9 Infection with Grade 3/4 neutropenia 0 6 Diarrhea 4 9 The following adverse reactions occurred more frequently in patients who were fully vitamin supplemented than in patients who were never supplemented: hypertension (11% versus 3%), chest pain (8% versus 6%), thrombosis/embolism (6% versus 3%).

Additional Experience Across Clinical Trials Sepsis, with or without neutropenia, including fatal cases: 1% Severe esophagitis, resulting in hospitalization: <1%

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ALIMTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System — immune-mediated hemolytic anemia Gastrointestinal — colitis, pancreatitis General Disorders and Administration Site Conditions — edema Injury, poisoning, and procedural complications — radiation recall Respiratory — interstitial pneumonitis Skin — Serious and fatal bullous skin conditions, Stevens-Johnson syndrome, and toxic epidermal necrolysis

Adverse reaction frequency tables (US label) US FDA label
Table 2: Adverse Reactions Occurring in ≥20% of Patients in KEYNOTE-189
a Graded per NCI CTCAE version 4.03.
b Includes asthenia and fatigue.
c Includes genital rash, rash, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, and rash pustular.
ALIMTA Pembrolizumab Platinum Chemotherapy n=405Placebo ALIMTA Platinum Chemotherapy n=202
Adverse ReactionAll Gradesa (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
Gastrointestinal Disorders
Nausea 56 3.5 52 3.5
Constipation 35 1.0 32 0.5
Diarrhea 31 5 21 3.0
Vomiting 24 3.7 23 3.0
General Disorders and Administration Site Conditions
Fatigueb56 12 58 6
Pyrexia 20 0.2 15 0
Metabolism and Nutrition Disorders
Decreased appetite 28 1.5 30 0.5
Skin and Subcutaneous Tissue Disorders
Rashc25 2.0 17 2.5
Respiratory, Thoracic and Mediastinal Disorders
Cough 21 0 28 0
Dyspnea 21 3.7 26 5
Table 3: Laboratory Abnormalities Worsened from Baseline in ≥20% of Patients in KEYNOTE-189
a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: ALIMTA/pembrolizumab/platinum chemotherapy (range: 381 to 401 patients) and placebo/ALIMTA/platinum chemotherapy (range: 184 to 197 patients).
b Graded per NCI CTCAE version 4.03.
ALIMTA Pembrolizumab Platinum ChemotherapyPlacebo ALIMTA Platinum Chemotherapy
Laboratory TestaAll Gradesb %Grades 3-4 %All Grades %Grades 3-4 %
Chemistry
Hyperglycemia 63 9 60 7
Increased ALT 47 3.8 42 2.6
Increased AST 47 2.8 40 1.0
Hypoalbuminemia 39 2.8 39 1.1
Increased creatinine 37 4.2 25 1.0
Hyponatremia 32 7 23 6
Hypophosphatemia 30 10 28 14
Increased alkaline phosphatase 26 1.8 29 2.1
Hypocalcemia 24 2.8 17 0.5
Hyperkalemia 24 2.8 19 3.1
Hypokalemia 21 5 20 5
Hematology
Anemia 85 17 81 18
Lymphopenia 64 22 64 25
Neutropenia 48 20 41 19
Thrombocytopenia 30 12 29 8
Table 4: Adverse Reactions Occurring in ≥5% of Fully Vitamin-Supplemented Patients Receiving ALIMTA in Combination with Cisplatin Chemotherapy in Study JMDB
a NCI CTCAE version 2.0.
Adverse ReactionaALIMTA/Cisplatin (N=839)Gemcitabine/Cisplatin (N=830)
All Grades (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
All adverse reactions90 37 91 53
Laboratory
Hematologic
Anemia 33 6 46 10
Neutropenia 29 15 38 27
Thrombocytopenia 10 4 27 13
Renal
Elevated creatinine 10 1 7 1
Clinical
Constitutional symptoms
Fatigue 43 7 45 5
Gastrointestinal
Nausea 56 7 53 4
Vomiting 40 6 36 6
Anorexia 27 2 24 1
Constipation 21 1 20 0
Stomatitis/pharyngitis 14 1 12 0
Diarrhea 12 1 13 2
Dyspepsia/heartburn 5 0 6 0
Neurology
Sensory neuropathy 9 0 12 1
Taste disturbance 8 0 9 0
Dermatology/Skin
Alopecia 12 0 21 1
Rash/Desquamation 7 0 8 1
Table 5: Adverse Reactions Occurring in ≥5% of Patients Receiving ALIMTA in Study JMEN
a NCI CTCAE version 3.0.
Adverse ReactionaALIMTA (N=438)Placebo (N=218)
All Grades (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
All adverse reactions66 16 37 4
Laboratory
Hematologic
Anemia 15 3 6 1
Neutropenia 6 3 0 0
Hepatic
Increased ALT 10 0 4 0
Increased AST 8 0 4 0
Clinical
Constitutional symptoms
Fatigue 25 5 11 1
Gastrointestinal
Nausea 19 1 6 1
Anorexia 19 2 5 0
Vomiting 9 0 1 0
Mucositis/stomatitis 7 1 2 0
Diarrhea 5 1 3 0
Infection5 2 2 0
Neurology
Sensory neuropathy 9 1 4 0
Dermatology/Skin
Rash/desquamation 10 0 3 0
Table 6: Adverse Reactions Occurring in ≥5% of Patients Receiving ALIMTA in PARAMOUNT
a NCI CTCAE version 3.0.
Adverse ReactionaALIMTA (N=333)Placebo (N=167)
All Grades (%)Grade 3-4 (%)All Grades (%)Grades 3-4 (%)
All adverse reactions53 17 34 4.8
Laboratory
Hematologic
Anemia 15 4.8 4.8 0.6
Neutropenia 9 3.9 0.6 0
Clinical
Constitutional symptoms
Fatigue 18 4.5 11 0.6
Gastrointestinal
Nausea 12 0.3 2.4 0
Vomiting 6 0 1.8 0
Mucositis/stomatitis 5 0.3 2.4 0
General disorders
Edema 5 0 3.6 0
Table 7: Adverse Reactions Occurring in ≥5% of Fully Supplemented Patients Receiving ALIMTA in Study JMEI
a NCI CTCAE version 2.0.
Adverse ReactionaALIMTA (N=265)Docetaxel (N=276)
All Grades (%)Grades 3-4 (%)All Grade (%)Grades 3-4 (%)
Laboratory
Hematologic
Anemia 19 4 22 4
Neutropenia 11 5 45 40
Thrombocytopenia 8 2 1 0
Hepatic
Increased ALT 8 2 1 0
Increased AST 7 1 1 0
Clinical
Gastrointestinal
Nausea 31 3 17 2
Anorexia 22 2 24 3
Vomiting 16 2 12 1
Stomatitis/pharyngitis 15 1 17 1
Diarrhea 13 0 24 3
Constipation 6 0 4 0
Constitutional symptoms
Fatigue 34 5 36 5
Fever 8 0 8 0
Dermatology/Skin
Rash/desquamation 14 0 6 0
Pruritus 7 0 2 0
Alopecia 6 1 38 2
Table 8: Adverse Reactions Occurring in ≥5% of Fully Supplemented Subgroup of Patients Receiving ALIMTA/Cisplatin in Study JMCHa
a In Study JMCH, 226 patients received at least one dose of ALIMTA in combination with cisplatin and 222 patients received at least one dose of cisplatin. Table 8 provides the ADRs for subgroup of patients treated with ALIMTA in combination with cisplatin (168 patients) or cisplatin alone (163 patients) who received full supplementation with folic acid and vitamin B12 during study therapy.
b NCI CTCAE version 2.0.
Adverse ReactionbALIMTA/cisplatin (N=168)Cisplatin (N=163)
All Grades (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
Laboratory
Hematologic
Neutropenia 56 23 13 3
Anemia 26 4 10 0
Thrombocytopenia 23 5 9 0
Renal
Elevated creatinine 11 1 10 1
Decreased creatinine clearance 16 1 18 2
Clinical
Eye Disorder
Conjunctivitis 5 0 1 0
Gastrointestinal
Nausea 82 12 77 6
Vomiting 57 11 50 4
Stomatitis/pharyngitis 23 3 6 0
Anorexia 20 1 14 1
Diarrhea 17 4 8 0
Constipation 12 1 7 1
Dyspepsia 5 1 1 0
Constitutional Symptoms
Fatigue 48 10 42 9
Metabolism and Nutrition
Dehydration 7 4 1 1
Neurology
Sensory neuropathy 10 0 10 1
Taste disturbance 8 0 6 0
Dermatology/Skin
Rash 16 1 5 0
Alopecia 11 0 6 0
Table 9: Exploratory Subgroup Analysis of Selected Grade 3/4 Adverse Reactions Occurring in Patients Receiving ALIMTA in Combination with Cisplatin with or without Full Vitamin Supplementation in Study JMCHa
a NCI CTCAE version 2.0.
Grade 3-4 Adverse ReactionsFully Supplemented Patients N=168 (%) Never Supplemented Patients N=32 (%)
Neutropenia 23 38
Thrombocytopenia 5 9
Vomiting 11 31
Febrile neutropenia 1 9
Infection with Grade 3/4 neutropenia 0 6
Diarrhea 4 9

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, ALIMTA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on ALIMTA use in pregnant women. In animal reproduction studies, intravenous administration of pemetrexed to pregnant mice during the period of organogenesis was teratogenic, resulting in developmental delays and malformations at doses lower than the recommended human dose of 500 mg/m 2 [see Data].

Advise pregnant women of the potential risk to a fetus [see Use in Special Populations (8.3)]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Pemetrexed was teratogenic in mice.

Daily dosing of pemetrexed by intravenous injection to pregnant mice during the period of organogenesis increased the incidence of fetal malformations (cleft palate; protruding tongue; enlarged or misshaped kidney; and fused lumbar vertebra) at doses (based on BSA) 0.03 times the human dose of 500 mg/m 2. At doses, based on BSA, greater than or equal to 0.0012 times the 500 mg/m 2 human dose, pemetrexed administration resulted in dose-dependent increases in developmental delays (incomplete ossification of talus and skull bone; and decreased fetal weight).

Mechanism of action

12.1 Mechanism of Action ALIMTA is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.

Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Pemetrexed inhibited the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052) and showed synergistic effects when combined with cisplatin. Based on population pharmacodynamic analyses, the depth of the absolute neutrophil counts (ANC) nadir correlates with the systemic exposure to pemetrexed and supplementation with folic acid and vitamin B12. There is no cumulative effect of pemetrexed exposure on ANC nadir over multiple treatment cycles.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).

Excretion Pemetrexed is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption The pharmacokinetics of pemetrexed when ALIMTA was administered as a single agent in doses ranging from 0.2 to 838 mg/m 2 infused over a 10-minute period have been evaluated in 426 cancer patients with a variety of solid tumors. Pemetrexed total systemic exposure (AUC) and maximum plasma concentration (C max) increased proportionally with increase of dose.

The pharmacokinetics of pemetrexed did not change over multiple treatment cycles. Distribution Pemetrexed has a steady-state volume of distribution of 16.1 liters. In vitro studies indicated that pemetrexed is 81% bound to plasma proteins. Elimination The total systemic clearance of pemetrexed is 91.8 mL/min and the elimination half-life of pemetrexed is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min).

As renal function decreases, the clearance of pemetrexed decreases and exposure (AUC) of pemetrexed increases. Metabolism Pemetrexed is not metabolized to an appreciable extent. Excretion Pemetrexed is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.

In vitro studies indicated that pemetrexed is a substrate of OAT3 (organic anion transporter 3), a transporter that is involved in the active secretion of pemetrexed. Specific Populations Age (26 to 80 years) and sex had no clinically meaningful effect on the systemic exposure of pemetrexed based on population pharmacokinetic analyses.

Racial Groups The pharmacokinetics of pemetrexed were similar in Whites and Blacks or African Americans. Insufficient data are available for other ethnic groups. Patients with Hepatic Impairment Pemetrexed has not been formally studied in patients with hepatic impairment. No effect of elevated AST, ALT, or total bilirubin on the PK of pemetrexed was observed in clinical studies.

Patients with Renal Impairment Pharmacokinetic analyses of pemetrexed included 127 patients with impaired renal function. Plasma clearance of pemetrexed decreases as renal function decreases, with a resultant increase in systemic exposure. Patients with creatinine clearances of 45, 50, and 80 mL/min had 65%, 54%, and 13% increases, respectively in systemic exposure (AUC) compared to patients with creatinine clearance of 100 mL/min [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].

Third-Space Fluid The pemetrexed plasma concentrations in patients with various solid tumors with stable, mild to moderate third-space fluid were comparable to those observed in patients without third space fluid collections. The effect of severe third space fluid on pharmacokinetics is not known. Drug Interaction Studies Drugs Inhibiting OAT3 Transporter Ibuprofen, an OAT3 inhibitor, administered at 400 mg four times a day decreased the clearance of pemetrexed and increased its exposure (AUC) by approximately 20% in patients with normal renal function (creatinine clearance >80 mL/min).

In Vitro Studies Pemetrexed is a substrate for OAT3. Ibuprofen, an OAT3 inhibitor inhibited the uptake of pemetrexed in OAT3-expressing cell cultures with an average [I u ]/IC 50 ratio of 0.38. In vitro data predict that at clinically relevant concentrations, other NSAIDs (naproxen, diclofenac, celecoxib) would not inhibit the uptake of pemetrexed by OAT3 and would not increase the AUC of pemetrexed to a clinically significant extent. [see Drug Interactions (7)].

Pemetrexed is a substrate for OAT4. In vitro, ibuprofen and other NSAIDs (naproxen, diclofenac, celecoxib) are not inhibitors of OAT4 at clinically relevant concentrations. Aspirin Aspirin, administered in low to moderate doses (325 mg every 6 hours), does not affect the pharmacokinetics of pemetrexed. Cisplatin Cisplatin does not affect the pharmacokinetics of pemetrexed and the pharmacokinetics of total platinum are unaltered by pemetrexed.

Vitamins Neither folic acid nor vitamin B12 affect the pharmacokinetics of pemetrexed. Drugs Metabolized by Cytochrome P450 Enzymes In vitro studies suggest that pemetrexed does not inhibit the clearance of drugs metabolized by CYP3A, CYP2D6, CYP2C9, and CYP1A2.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Alimta · Eli Lilly and Company [US FDA-approved label, version 59, May 19, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5a860f3-37ec-429c-ae04-9c88d7c55c08
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .